Money
Merck & Co. Implements Strategies to Address KEYTRUDA Exclusivity Loss
Merck & Co. is actively pursuing measures to counteract the anticipated loss of exclusivity for its leading drug, KEYTRUDA, as it approaches a critical market transition.
Editorial Staff
1 min read
As KEYTRUDA nears the end of its exclusivity period, Merck & Co. is implementing strategic initiatives aimed at maintaining its market position.
These measures are likely to include enhancements in operational capacity and adjustments in product offerings to mitigate potential revenue impacts.
The company's approach reflects a broader trend in the pharmaceutical industry, where firms are increasingly focused on sustaining competitive advantages in the face of patent expirations.